Academic Lead: Prof. Trevor Robbins, University of Cambridge, UK
EFPIA Lead: Dr. Mark Tricklebank, Eli Lilly and Co Ltd, UK
This project is clearly one that is best done by collaboration between academia and industry. The academic partners bring special expertise in test development and in the neural validation of the tests. The industrial partners are best positioned to add to this: (i) cross-laboratory validation (ii) providing the novel key cognitive enhancing candidates upon which the project hinges and (iii) have the capacity to deliver mass testing of selected assays and models(perturbations) for schizophrenia, including e.g. provision of suitable transgenic mouse models. The interactive aspects of this WP would ensure its synergistic aspects and its possibilities for further clinical translation. The focus on cortical-hippocampal function and dysfunction gives a behavioural dimension to the electrophysiology work and imaging work described in WP01 and WP03 and a consistent pharmacological approach across both work plans will further assist the validation and translational aspects.